# US 2026/0232734 A1 · Therapeutic T-Cell Receptors Targeting KRAS G12D

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0232734 A1
- Document ID: US20260232734A1
- Status: Published application
- Kind: A1
- Application number: 19/159,272
- Filed: 2024-02-23
- Published: 2026-08-13
- Earliest claimed: 2023-02-27
- Applicants: Adaptive Biotechnologies Corporation
- Inventors: Mark Klinger; Soyoung Oh; Sascha Rutz; Rena Whei-Ming Yang; Erik Yusko; Peter Ebert; Kate Halliwell Senger
- Web page: https://patentgrep.com/patent/US20260232734A1

## CPC

- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 39/0011: {Cancer antigens}
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 31/7076: containing purines, e.g. adenosine, adenylic acid
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/24: Antigen-presenting cells [APC]
- A61K 40/32: T-cell receptors [TCR]
- A61K 40/42: Cancer antigens
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C07K 14/4748: {Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE}
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- A61K 2039/5156: {expressing foreign proteins}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2239/28: Expressing multiple CARs, TCRs or antigens
- A61K 2239/54: Pancreas
- C12N 2510/00: Genetically modified cells
- C12N 2740/16043: viral genome or elements thereof as genetic vector
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Disclosed herein are therapeutic T cell receptors (TCRs) that bind to a KRAS G12D neoantigen, engineered cells expressing such TCRs, pharmaceutical compositions comprising such cells, and methods of treatment using such cells or pharmaceutical compositions.

## Claims

### Claim 1

A recombinant T cell receptor (TCR) that binds to a Kirsten rat sarcoma viral oncogene homolog (KRAS) G12D neoantigen comprising:
a TCR-alpha chain comprising a TCR-alpha variable region; and
a TCR-beta chain comprising a TCR-beta variable region;
wherein the TCR-alpha variable region comprises the following:
a CDR1 comprising the amino acid sequence SEQ ID NO: 7,
a CDR2 comprising the amino acid sequence SEQ ID NO: 8, and
a CDR3 comprising amino the acid sequence SEQ ID NO: 9; and
wherein the TCR-beta variable region comprises the following:
a CDR1 comprising the amino acid sequence SEQ ID NO: 3,
a CDR2 comprising the amino acid sequence SEQ ID NO: 4, and
a CDR3 comprising the amino acid sequence SEQ ID NO: 6.

### Claim 2 (depends on 1)

The recombinant TCR of claim 1, wherein the TCR-alpha chain variable region comprises at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 10 and the TCR-beta chain variable region comprises at least 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 11.

### Claim 3 (depends on 1, 2)

The recombinant TCR of claim 1 or 2, wherein the TCR-alpha chain comprises at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 12.

### Claim 4 (depends on 1, 2, 3)

The recombinant TCR of any one of claims 1-3, wherein the TCR-beta chain comprises at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 13, SEQ ID NO: 14, or 15.

### Claim 5 (depends on 1, 2, 3, 4)

The recombinant TCR of any one of claims 1-4, wherein the TCR binds the KRAS G12D neoantigen in a subject who is HLA-A*11:01 positive.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The recombinant TCR of any one of claims 1-5, wherein the TCR is HLA 11:01 restricted.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The recombinant TCR of any one of claims 1-6, wherein the TCR activates a T cell upon binding to the KRAS G12D neoantigen.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The recombinant TCR of any one of claims 1-7, wherein the neoantigen comprises SEQ ID NO: 1 or SEQ ID NO: 2.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

An engineered cell that expresses the recombinant TCR of any one of claims 1-8.

### Claim 10 (depends on 9)

The engineered cell of claim 9 wherein the cell is an iPSC-derived T cell, a patient-derived autologous T cell, a donor-derived T cell, or an iPSC cell, optionally wherein the patient-derived autologous T cell, donor-derived T cell, or iPSC-derived T cell is a CD8+ T cell.

### Claim 11 (depends on 9, 10)

The engineered cell of claim 9 or 10 wherein the cell is an iPSC-derived T cell.

### Claim 12 (depends on 9, 10)

The engineered cell of claim 9 or 10 wherein the cell is a patient-derived autologous T cell.

### Claim 13 (depends on 9, 10, 11, 12)

The engineered cell of any one of claims 9-12, wherein the T cell, which is optionally an iPSC-derived T cell, or iPSC cell comprises at least one nucleic acid sequence comprising at least one heterologous gene inserted into one or both of:
a. an endogenous T cell receptor alpha subunit constant gene (TRAC), and
b. an endogenous T cell receptor beta subunit constant gene (TRBC),
wherein the at least one heterologous gene comprises at least one of:
a. a variable region of a heterologous human TCR-a chain gene, and
b. a variable region of a heterologous human TCR-β chain gene.

### Claim 14 (depends on 9, 10, 11, 12, 13)

The engineered cell of any one of claims 9-13, wherein the at least one nucleic acid sequence does not comprise a viral vector.

### Claim 15 (depends on 9, 10, 11, 12, 13, 14)

The engineered cell of any one of claims 9-14, wherein the T cell, which is optionally an iPSC-derived T cell, or iPSC cell comprises at least one nucleic acid sequence comprising at least one heterologous gene non-virally inserted into one or both of:
a. an endogenous T cell receptor alpha subunit constant gene (TRAC), and
b. an endogenous T cell receptor beta subunit constant gene (TRBC),
wherein the at least one heterologous gene comprises at least one of:
c. a variable region of a heterologous human TCR-a chain gene, and
d. a variable region of a heterologous human TCR-β chain gene.

### Claim 16 (depends on 9, 10, 11, 12, 13, 14, 15)

The engineered cell of any one of claims 9-15, wherein the nucleic acid comprises a heterologous TCR-alpha subunit chain and a heterologous TCR-beta subunit chain.

### Claim 17 (depends on 9, 10, 11, 12, 13, 14, 15, 16)

The engineered cell of any one of claims 9-16, wherein the nucleic acid is inserted into the endogenous TRAC and the endogenous TRBC is deleted.

### Claim 18 (depends on 9, 10, 11, 12, 13, 14, 15, 16, 17)

The engineered cell of any one of claims 9-17, wherein the nucleic acid comprises the variable region and constant region of a heterologous human TCR-β chain gene and the variable region of a heterologous human TCR-a chain gene.

### Claim 19 (depends on 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The engineered cell of any one of claims 9-18, wherein the nucleic acid comprises, from N-terminus to C-terminus:
a. a first self-cleaving peptide sequence;
b. the variable region and constant region of a heterologous human TCR-β chain gene;
c. a second self-cleaving peptide sequence;
d. the variable region of a heterologous human TCR-a chain gene; and
e. a portion of the N-terminus of the endogenous TRAC.

### Claim 20 (depends on 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The engineered cell of any one of claims 9-19, wherein the at least one heterologous gene replaces a placeholder TCR variable region.

### Claim 21 (depends on 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

A pharmaceutical composition comprising the engineered T cells of any one of claims 9-20.

### Claim 22 (depends on 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

A method for treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the engineered T cell of any one of claims 9-20 or the pharmaceutical composition of claim 21.

### Claim 23 (depends on 22)

The method of claim 22, wherein the subject is HLA-A*11:01 positive.

### Claim 24 (depends on 22, 23)

The method of claim 22 or 23, wherein the subject received prior therapy for treating the cancer.

### Claim 25 (depends on 22, 23, 24)

The method of any one of claims 22-24, wherein the cancer is locally advanced, unresectable, metastatic, refractory, or recurrent cancer.

### Claim 26 (depends on 22, 23, 24, 25)

The method of any one of claims 22-25, wherein engineered T cells are administered at a dose of ≥7.5×108 cells and ≤4.5×1010 cells.

### Claim 27 (depends on 22, 23, 24, 25, 26)

The method of any one of claims 22-26, wherein the engineered T cells are administered via intravenous infusion.

### Claim 28 (depends on 22, 23, 24, 25, 26, 27)

The method of any one of claims 22-27 wherein the cancer is selected from the group consisting of: pancreatic cancer (e.g., pancreatic ductal adenocarcinoma (PDAC)), colorectal cancer (CRC), lung cancer (e.g., non-small cell lung cancer).

### Claim 29 (depends on 22, 23, 24, 25, 26, 27, 28)

The method of any one of claims 22-28, further comprising administering an anti-PD-L1 antibody.

### Claim 30 (depends on 29)

The method of claim 29, wherein the anti-PD-L1 antibody is atezolizumab.

### Claim 31 (depends on 22, 23, 24, 25, 26, 27, 28, 29, 30)

The method of any one of claims 22-30, wherein the method further comprises administering to the subject a lymphodepleting chemotherapy regimen prior to administration of the engineered T cells.

### Claim 32 (depends on 31)

The method of claim 31, wherein the lymphodepleting chemotherapy regimen comprises fludarabine and cyclophosphamide.

### Claim 33

A recombinant T cell receptor (TCR) that binds to a KRAS G12D neoantigen, comprising a TCR-alpha chain variable region and a TCR-beta chain variable region, wherein
the TCR-alpha chain variable region comprises:
a. a CDR1 sequence comprising an amino acid sequence set forth in SEQ ID NOs: 19, 29, 39, 49, 59, 69, 79, or 89; and
b. a CDR2 sequence comprising an amino acid sequence set forth in SEQ ID NOs: 20, 30, 40, 50, 60, 70, 80, or 90; and
c. a CDR3 sequence comprising an amino acid sequence set forth in SEQ ID NOs: 21, 31, 41, 51, 61, 71, 81, or 91; and
the TCR-beta chain variable region comprises:
d. a CDR1 sequence comprising an amino acid sequence set forth in SEQ ID NOs: 16, 26, 36, 46, 56, 66, 76, or 86; and
e. a CDR2 sequence comprising an amino acid sequence set forth in SEQ ID NOs: 17, 27, 37, 47, 57, 67, 77, or 87; and
f. a CDR3 sequence comprising an amino acid sequence set forth in SEQ ID NOs: 18, 28, 38, 48, 58, 68, 78, or 88.

### Claim 34 (depends on 33)

The recombinant TCR of claim 33, wherein the TCR comprises:
a. a TCR-alpha chain variable region comprising a CDR1, a CDR2, and a CDR3 comprising amino acid sequences SEQ ID NOs: 19, 20, and 21, respectively, and a TCR-beta chain variable region comprising a CDR1, a CDR2, and a CDR3 comprising amino acid sequences SEQ ID NOs: 16, 17, and 18, respectively; or
b. a TCR-alpha chain variable region comprising a CDR1, a CDR2, and a CDR3 comprising amino acid sequences SEQ ID NOs: 29, 30, and 31, respectively, and a TCR-beta chain variable region comprising a CDR1, a CDR2, and a CDR3 comprising amino acid sequences SEQ ID NOs: 26, 27, and 28, respectively; or
c. a TCR-alpha chain variable region comprising a CDR1, a CDR2, and a CDR3 comprising amino acid sequences SEQ ID NOs: 39, 40, and 41, respectively, and a TCR-beta chain variable region comprising a CDR1, a CDR2, and a CDR3 comprising amino acid sequences SEQ ID NOs: 36, 37, and 38, respectively; or
d. a TCR-alpha chain variable region comprising a CDR1, a CDR2, and a CDR3 comprising amino acid sequences SEQ ID NOs: 49, 50, and 51, respectively, and a TCR-beta chain variable region comprising a CDR1, a CDR2, and a CDR3 comprising amino acid sequences SEQ ID NOs: 46, 47, and 48, respectively; or
e. a TCR-alpha chain variable region comprising a CDR1, a CDR2, and a CDR3 comprising amino acid sequences SEQ ID NOs: 59, 60, and 61, respectively, and a TCR-beta chain variable region comprising a CDR1, a CDR2, and a CDR3 comprising amino acid sequences SEQ ID NOs: 56, 57, and 58, respectively; or
f. a TCR-alpha chain variable region comprising a CDR1, a CDR2, and a CDR3 comprising amino acid sequences SEQ ID NOs: 69, 70, and 71, respectively, and a TCR-beta chain variable region comprising a CDR1, a CDR2, and a CDR3 comprising amino acid sequences SEQ ID NOs: 66, 67, and 68, respectively; or
g. a TCR-alpha chain variable region comprising a CDR1, a CDR2, and a CDR3 comprising amino acid sequences SEQ ID NOs: 79, 80, and 81, respectively, and a TCR-beta chain variable region comprising a CDR1, a CDR2, and a CDR3 comprising amino acid sequences SEQ ID NOs: 76, 77, and 78, respectively; or
h. a TCR-alpha chain variable region comprising a CDR1, a CDR2, and a CDR3 comprising amino acid sequences SEQ ID NOs: 89, 90, and 91, respectively, and a TCR-beta chain variable region comprising a CDR1, a CDR2, and a CDR3 comprising amino acid sequences SEQ ID NOs: 86, 87, and 88, respectively.

### Claim 35 (depends on 33, 34)

The recombinant TCR of claim 33 or 34, wherein the TCR-alpha chain variable region comprises at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 22, 32, 42, 52, 62, 72, 82, or 92.

### Claim 36 (depends on 33, 34, 35)

The recombinant TCR of any one of claims 33-35, wherein the TCR-beta chain variable region comprises at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 23, 33, 43, 53, 63, 73, 83, or 93.

### Claim 37 (depends on 33, 34, 35, 36)

The recombinant TCR of any one of claims 33-36, comprising:
a. a TCR-alpha chain variable region and a TCR-beta chain variable region having at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 22 and SEQ ID: 23, respectively; or
b. a TCR-alpha chain variable region and a TCR-beta chain variable region having at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 32 and SEQ ID: 33, respectively; or
c. a TCR-alpha chain variable region and a TCR-beta chain variable region having at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 42 and SEQ ID: 43, respectively; or
d. a TCR-alpha chain variable region and a TCR-beta chain variable region having at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 52 and SEQ ID: 53, respectively; or
e. a TCR-alpha chain variable region and a TCR-beta chain variable region having at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 62 and SEQ ID: 63, respectively; or
f. a TCR-alpha chain variable region and a TCR-beta chain variable region having at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 72 and SEQ ID: 73, respectively; or
g. a TCR-alpha chain variable region and a TCR-beta chain variable region having at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 82 and SEQ ID: 83, respectively; or
h. a TCR-alpha chain variable region and a TCR-beta chain variable region having at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 92 and SEQ ID: 93, respectively.

### Claim 38 (depends on 33, 34, 35, 36, 37)

The recombinant TCR of any one of claims 33-37, comprising:
a. a TCR-alpha chain and a TCR-beta chain having at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 24 and SEQ ID: 25, respectively; or
b. a TCR-alpha chain and a TCR-beta chain having at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 34 and SEQ ID: 35, respectively; or
c. a TCR-alpha chain and a TCR-beta chain having at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 44 and SEQ ID: 45, respectively; or
d. a TCR-alpha chain and a TCR-beta chain having at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 54 and SEQ ID: 55, respectively; or
e. a TCR-alpha chain and a TCR-beta chain having at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 64 and SEQ ID: 65, respectively; or
f. a TCR-alpha chain and a TCR-beta chain having at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 74 and SEQ ID: 75, respectively; or
g. a TCR-alpha chain and a TCR-beta chain having at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 84 and SEQ ID: 85, respectively; or
h. a TCR-alpha chain and a TCR-beta chain having at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to SEQ ID NO: 94 and SEQ ID: 95, respectively.

### Claim 39 (depends on 33, 34, 35, 36, 37, 38)

The recombinant TCR of any one of claims 33-38, wherein the TCR binds the KRAS G12D neoantigen in a subject who is HLA-A*11:01 positive.

### Claim 40 (depends on 33, 34, 35, 36, 37, 38, 39)

The recombinant TCR of any one of claims 33-39, wherein the TCR is HLA 11:01 restricted.

### Claim 41 (depends on 33, 34, 35, 36, 37, 38, 39, 40)

The recombinant TCR of any one of claims 33-40, wherein the TCR activates a T cell upon binding to the KRAS G12D neoantigen.

### Claim 42 (depends on 33, 34, 35, 36, 37, 38, 39, 40, 41)

The recombinant TCR of any one of claims 33-41, wherein the neoantigen comprises SEQ ID NO: 1 or SEQ ID NO: 2.

### Claim 43 (depends on 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

An engineered cell that expresses the recombinant TCR of any one of claims 33-42.

### Claim 44 (depends on 43)

The engineered cell of claim 43 wherein the cell is an iPSC-derived T cell, a patient-derived autologous T cell, a donor-derived T cell, or an iPSC cell, optionally wherein the patient-derived autologous T cell, donor-derived T cell, or iPSC-derived T cell is a CD8+ T cell.

### Claim 45 (depends on 43, 44)

The engineered cell of claim 43 or 44 wherein the cell is an iPSC-derived T cell.

### Claim 46 (depends on 43, 44)

The engineered cell of claim 43 or 44 wherein the cell is a patient-derived autologous T cell.

### Claim 47 (depends on 43, 44, 45, 46)

The engineered cell of any one of claims 43-46, wherein the T cell, which is optionally an iPSC-derived T cell, or iPSC cell comprises at least one nucleic acid sequence comprising at least one heterologous gene inserted into one or both of:
a. an endogenous T cell receptor alpha subunit constant gene (TRAC), and
b. an endogenous T cell receptor beta subunit constant gene (TRBC),
wherein the at least one heterologous gene comprises at least one of:
e. a variable region of a heterologous human TCR-a chain gene, and
f. a variable region of a heterologous human TCR-β chain gene.

### Claim 48 (depends on 43, 44, 45, 46, 47)

The engineered cell of claim 43-47, wherein the at least one nucleic acid sequence does not comprise a viral vector.

### Claim 49 (depends on 43, 44, 45, 46, 47, 48)

The engineered cell of claim 43-48, wherein the T cell, which is optionally an iPSC-derived T cell, or iPSC cell comprises at least one nucleic acid sequence comprising at least one heterologous gene non-virally inserted into one or both of:
a. an endogenous T cell receptor alpha subunit constant gene (TRAC), and
b. an endogenous T cell receptor beta subunit constant gene (TRBC),
wherein the at least one heterologous gene comprises at least one of:
g. a variable region of a heterologous human TCR-a chain gene, and
h. a variable region of a heterologous human TCR-β chain gene.

### Claim 50 (depends on 43, 44, 45, 46, 47, 48, 49)

The engineered cell of claim 43-49, wherein the nucleic acid comprises a heterologous TCR-alpha subunit chain and a heterologous TCR-beta subunit chain.

### Claim 51 (depends on 43, 44, 45, 46, 47, 48, 49, 50)

The engineered cell of claim 43-50, wherein the nucleic acid is inserted into the endogenous TRAC and the endogenous TRBC is deleted.

### Claim 52 (depends on 43, 44, 45, 46, 47, 48, 49, 50, 51)

The engineered cell of claim 43-51, wherein the nucleic acid comprises the variable region and constant region of a heterologous human TCR-β chain gene and the variable region of a heterologous human TCR-a chain gene.

### Claim 53 (depends on 43, 44, 45, 46, 47, 48, 49, 50, 51, 52)

The engineered cell of claim 43-52, wherein the nucleic acid comprises, from N-terminus to C-terminus:
a. a first self-cleaving peptide sequence;
b. the variable region and constant region of a heterologous human TCR-β chain gene;
c. a second self-cleaving peptide sequence;
d. the variable region of a heterologous human TCR-a chain gene; and
e. a portion of the N-terminus of the endogenous TRAC.

### Claim 54 (depends on 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53)

The engineered cell of claim 43-53, wherein the at least one heterologous gene replaces a placeholder TCR variable region.

### Claim 55 (depends on 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54)

A pharmaceutical composition comprising the engineered T cells of any one of claims 43-54.

### Claim 56 (depends on 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55)

A method for treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the engineered T cell of any one of claims 43-54 or the pharmaceutical composition of claim 55.

### Claim 57 (depends on 56)

The method of claim 56, wherein the subject is HLA-A*11:01 positive.

### Claim 58 (depends on 56, 57)

The method of claim 56 or 57, wherein the subject received prior therapy for treating the cancer.

### Claim 59 (depends on 56, 57, 58)

The method of any one of claims 56-58, wherein the cancer is locally advanced, unresectable, metastatic, refractory, or recurrent cancer.

### Claim 60 (depends on 56, 57, 58, 59)

The method of any one of claims 56-59, wherein engineered T cells are administered at a dose of ≥7.5×108 cells and ≤4.5×1010 cells.

### Claim 61 (depends on 56, 57, 58, 59, 60)

The method of any one of claims 56-60, wherein the engineered T cells are administered via intravenous infusion.

### Claim 62 (depends on 56, 57, 58, 59, 60, 61)

The method of any one of claims 56-61 wherein the cancer is selected from the group consisting of: pancreatic cancer (e.g., pancreatic ductal adenocarcinoma (PDAC)), colorectal cancer (CRC), lung cancer (e.g., non-small cell lung cancer).

### Claim 63 (depends on 56, 57, 58, 59, 60, 61, 62)

The method of any one of claims 56-62, further comprising administering an anti-PD-L1 antibody.

### Claim 64 (depends on 62)

The method of claim 62, wherein the anti-PD-L1 antibody is atezolizumab.

### Claim 65 (depends on 56, 57, 58, 59, 60, 61, 62, 63, 64)

The method of any one of claims 56-64, wherein the method further comprises administering to the subject a lymphodepleting chemotherapy regimen prior to administration of the engineered T cells.

### Claim 66 (depends on 65)

The method of claim 65, wherein the lymphodepleting chemotherapy regimen comprises fludarabine and cyclophosphamide.

### Claim 67

An engineered cell that expresses a recombinant TCR comprising:
a TCR-alpha chain comprising a TCR-alpha variable region; and
a TCR-beta chain comprising a TCR-beta variable region;
wherein the TCR-alpha variable region comprises the following:
a. a CDR1 comprising the amino acid sequence SEQ ID NO: 7,
b. a CDR2 comprising the amino acid sequence SEQ ID NO: 8, and
c. a CDR3 comprising amino the acid sequence SEQ ID NO: 9; and
wherein the TCR-beta variable region comprises the following:
d. a CDR1 comprising the amino acid sequence SEQ ID NO: 3,
e. a CDR2 comprising the amino acid sequence SEQ ID NO: 4, and
f. a CDR3 comprising the amino acid sequence SEQ ID NO: 6; and
wherein the T cell, which is optionally an iPSC-derived T cell, or iPSC cell comprises at least one nucleic acid sequence comprising at least one heterologous gene inserted into one or both of:
a. an endogenous T cell receptor alpha subunit constant gene (TRAC), and
b. an endogenous T cell receptor beta subunit constant gene (TRBC),
wherein the at least one heterologous gene comprises at least one of:
a. a variable region of a heterologous human TCR-a chain gene, and
b. a variable region of a heterologous human TCR-β chain gene; and
wherein intracellular delivery of the at least one heterologous gene comprises introducing the at least one heterologous gene using a viral vector.

### Claim 68

An engineered cell that expresses a recombinant TCR comprising:
a TCR-alpha chain comprising a TCR-alpha variable region; and
a TCR-beta chain comprising a TCR-beta variable region;
wherein the TCR-alpha chain variable region comprises at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 10 and the TCR-beta chain variable region comprises at least 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 11; and
wherein the T cell, which is optionally an iPSC-derived T cell, or iPSC cell comprises at least one nucleic acid sequence comprising at least one heterologous gene inserted into one or both of:
a. an endogenous T cell receptor alpha subunit constant gene (TRAC), and
b. an endogenous T cell receptor beta subunit constant gene (TRBC),
wherein the at least one heterologous gene comprises at least one of:
a. a variable region of a heterologous human TCR-a chain gene, and
b. a variable region of a heterologous human TCR-β chain gene; and
wherein intracellular delivery of the at least one heterologous gene comprises introducing the at least one heterologous gene using a viral vector.

### Claim 69

An engineered cell that expresses a recombinant TCR comprising:
a TCR-alpha chain comprising a TCR-alpha variable region; and
a TCR-beta chain comprising a TCR-beta variable region;
wherein the TCR-alpha chain comprises at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the amino acid sequence set forth in SEQ ID NO: 12; and
wherein the TCR-beta chain comprises at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% sequence identity to the amino acid sequence set forth in SEQ ID NO:
13, SEQ ID NO: 14, or 15; and
wherein the T cell, which is optionally an iPSC-derived T cell, or iPSC cell comprises at least one nucleic acid sequence comprising at least one heterologous gene inserted into one or both of:
a. an endogenous T cell receptor alpha subunit constant gene (TRAC), and
b. an endogenous T cell receptor beta subunit constant gene (TRBC),
wherein the at least one heterologous gene comprises at least one of:
a. a variable region of a heterologous human TCR-a chain gene, and
b. a variable region of a heterologous human TCR-β chain gene; and
wherein intracellular delivery of the at least one heterologous gene comprises introducing the at least one heterologous gene using a viral vector.

### Claim 70 (depends on 67, 68, 69)

A method of preparing the engineered cell of any one of claims 67-69 comprising
a. providing a cell, and
b. introducing at least one heterologous gene in a viral vector into the cell,
wherein the viral vector comprises a nucleic acid sequence encoding at least the TCR alpha subunit and/or the TCR beta subunit,
wherein optionally the TCR alpha and/or TCR beta subunits are inserted into the host cell at the TCR alpha locus and/or TCR beta locus, respectively, and/or at a locus outside of the endogenous TCR alpha locus and/or TCR beta locus.
